Miralinc Pharma
Pioneering Next Generation HDAC6i’s to advance life-changing disease cures for patients
Our Mission
Miralinc is advancing life-changing disease cures to patients with a focus on developing effective drug therapies for debilitating diseases of the peripheral and central nervous systems. Our name captures the process linking leading academic research scientists together with experts in human drug development to achieve the miracle that is a cure for patients.
Charcot-Marie-Tooth
A group of hereditary disorders that damage the nerves in the arms and legs.
Peripheral Neuropathies
Weakness, numbness, & pain from nerve damage, usually in the hands & feet.
Chemo-Induced
A nerve-damaging side effect of the common cancer treatment, chemotherapy
Our Company
Miralinc was founded with the initial support of the Hereditary Neuropathy Foundation (HNF) to advance a cure for Charcot-Marie-Tooth disease (CMT) and other peripheral neuropathies. Histone deacetylase subtype 6 (HDAC6) is the focus therapeutic target which has strong preclinical validation from academic research in animal models of peripheral neuropathies. To start, Miralinc is developing next-generation proprietary high cellular potency HDAC6 inhibitors (HDAC6i) that have been optimized for effective dosing in human patient populations. MRL-A102 is the company’s lead high-potency drug candidate for development in neuropathies.
Our Science
A large body of preclinical research has validated the therapeutic potential of HDAC6i to treat peripheral neuropathies, including CMT, Diabetic Neuropathy (DN), and Chemotherapy Induced Neuropathy (CIPN). In transgenic mouse models of diverse hereditary forms of CMT, including CMT1A and CMT2A, inhibiting HDAC6 reverses neurological disease symptoms. HDAC6i compounds have also been demonstrated to restore nerve function and prevent nerve damage in wild-type rodent models of CIPN and DN.
